Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
14.88 | 18.17 | 17.90 | 12.94 |
+8 more quarters Free account |
P/S ratio |
4.13 | 5.39 | 5.63 | 4.09 | |
P/FCF ratio |
17.93 | 21.20 | 21.44 | 15.01 | |
P/Operating CF |
78.84 | 74.48 | 68.97 | 35.99 | |
P/B ratio |
2.02 | 2.56 | 2.58 | 1.88 | |
Price to Tangible BV |
2.11 | 2.67 | 2.69 | 1.97 | |
EV/Sales |
3.79 | 4.98 | 5.27 | 3.74 | |
EV/EBITDA |
13.45 | 17.82 | 18.33 | 12.63 | |
EV/Operating CF |
12.56 | 14.82 | 15.18 | 10.50 | |
EV/FCF |
16.45 | 19.60 | 20.07 | 13.72 | |
Quick Ratio |
2.63 | 2.84 | 3.28 | 3.19 | |
Current Ratio |
3.34 | 3.57 | 4.13 | 4.06 | |
Net Debt/EBITDA |
(4.24) | (8.83) | (5.76) | (4.93) | |
Debt/Assets |
4.76% | 4.86% | 6.67% | 6.74% | |
Debt/Equity |
0.06 | 0.06 | 0.09 | 0.09 | |
Asset Turnover |
0.39 | 0.38 | 0.37 | 0.37 | |
Operating CF/Net income |
0.63 | 1.48 | 1.39 | 1.11 | |
Capex/Depreciation |
(2.35) | (2.27) | (2.00) | (1.79) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
38.03% | 42.81% | 41.86% | 39.29% | |
Selling, General and Administrative Expense of Revenue |
15.43% | 17.96% | 19.95% | 17.52% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
5.66% | 7.14% | 6.42% | 6.31% | |
Graham Net Nets |
0.13 | 0.11 | 0.11 | 0.15 | |
Graham Number |
539.34 | 537.71 | 538.44 | 540.43 | |
Earnings Yield |
6.72% | 5.50% | 5.59% | 7.73% | |
Free Cash Flow Yield |
5.58% | 4.72% | 4.66% | 6.66% | |
Revenue per Share |
41.74 | 34.67 | 37.13 | 36.24 | |
Operating CF per Share |
7.91 | 10.37 | 11.19 | 15.62 | |
Capex per Share |
(2.83) | (2.69) | (2.78) | (2.36) | |
Free Cash Flow per Share |
5.08 | 7.69 | 8.41 | 13.26 | |
Cash per Share |
77.77 | 84.17 | 82.27 | 81.50 | |
Shareholders Equity per Share |
308.48 | 302.15 | 298.82 | 298.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
308.48 | 302.15 | 298.82 | 298.82 | |
Free Cash Flow |
521.80 | 799.40 | 880.00 | 1,374.00 | |
Working Capital |
12,915.40 | 13,101.50 | 13,653.50 | 13,555.60 | |
Capital Expenditures |
(291.20) | (279.50) | (290.70) | (244.70) | |
Net Current Asset Value |
8,426.80 | 8,764.00 | 8,720.10 | 8,769.10 | |
EV/EBIT |
15.30 | 20.48 | 21.12 | 14.43 | |
Capex to Sales |
0.07 | 0.08 | 0.07 | 0.07 | |
Net Profit Margin |
30.23% | 20.17% | 21.74% | 38.89% | |
Price to Operating Income |
16.68 | 22.14 | 22.57 | 15.79 | |
| Other line items | |||||
Average Receivables |
6,087.70 | 5,646.00 | 5,976.50 | 5,897.10 | |
Average Payables |
941.60 | 866.30 | 864.25 | 700.55 | |
Average Inventory |
3,144.95 | 3,148.00 | 3,144.05 | 3,136.20 | |
Average Assets |
39,974.90 | 39,207.00 | 39,159.05 | 38,805.65 | |
Average Common Equity |
30,825.15 | 30,405.60 | 30,305.25 | 30,141.85 |
Columns are period end dates